NASDAQ$HROW
Harrow Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Announced third quarter 2022 financial results, highlighting FDA approval for IHEEZO and the launch of Fortisite and atropine.com.
Harrow announced its Q3 2022 results, marking an inflection point with FDA approval for IHEEZO, launch of Fortisite, and the sale of its non-ophthalmology compounded product line, focusing the company entirely on the U.S. ophthalmic pharmaceutical market.
- Received FDA approval for IHEEZO for ocular surface anesthesia.
- Launched Fortisite, a new suite of compounded products.
- Sold non-ophthalmology compounded product line to focus on the U.S. ophthalmic pharmaceutical market.
- Launched atropine.com to market compounded atropine formulations.
Headline financials
Revenue & EPS history
Harrow · Revenue · Quarterly
$22.8M
Forward guidance
No specific forward guidance was provided in the press release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+1.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+8.3%
Avg return
30 days after
52%
25 / 48 earnings
Positive
+49.3%
Q2 2024
Best reaction
-36.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -18.5% | -6.3% | |
| Q4 2025 | +2.3% | -32.2% | -34.1% | |
| Q3 2025 | +13.6% | +19.5% | +49.7% | |
| Q1 2025 | +3.4% | +6.5% | +25.4% | |
| Q4 2024 | -6.0% | +21.8% | +2.9% | |
| Q3 2024 | -14.1% | -23.9% | -28.9% | |
| Q2 2024 | +49.3% | +56.3% | +67.2% | |
| Q1 2024 | +40.0% | +44.5% | +57.3% | |
| Q4 2023 | +0.3% | +9.6% | +3.4% | |
| Q3 2023 | -36.0% | -30.2% | -21.7% | |
| Q2 2023 | -17.4% | -14.7% | -26.8% | |
| Q1 2023 | -20.5% | -24.1% | -26.9% | |
| Q4 2022 | +6.7% | +22.9% | +42.6% | |
| Q3 2022 | -4.2% | -9.4% | +10.5% | |
| Q2 2022 | +12.2% | +24.6% | +32.6% | |
| Q1 2022 | +3.3% | -5.3% | +15.3% | |
| Q4 2021 | +3.0% | -1.4% | -1.7% | |
| Q3 2021 | -4.9% | -3.3% | -21.1% | |
| Q2 2021 | -0.3% | -0.8% | +13.0% | |
| Q1 2021 | +15.8% | +14.5% | +14.0% | |
| Q4 2020 | +3.5% | +3.4% | -12.3% | |
| Q3 2020 | +25.8% | +30.0% | +19.9% | |
| Q2 2020 | +4.8% | +10.4% | +15.0% | |
| Q1 2020 | -5.8% | -9.7% | +36.5% | |
| Q4 2019 | -7.5% | -16.0% | -3.8% | |
| Q3 2019 | +18.6% | +16.1% | +33.8% | |
| Q2 2019 | -23.6% | -21.7% | -8.0% | |
| Q1 2019 | +10.1% | +16.5% | +26.6% | |
| Q4 2018 | -7.5% | -20.3% | -30.1% | |
| Q3 2018 | +7.2% | +23.0% | +38.4% | |
| Q2 2018 | +13.4% | +29.3% | +26.4% | |
| Q1 2018 | +9.3% | +5.3% | +6.2% | |
| Q4 2017 | -3.4% | -5.3% | -3.9% | |
| Q3 2017 | +5.7% | +19.1% | +7.6% | |
| Q2 2017 | -7.9% | -9.7% | -28.2% | |
| Q1 2017 | -4.8% | -12.6% | -22.5% | |
| Q4 2016 | +2.9% | +17.0% | +79.7% | |
| Q3 2016 | -9.8% | -13.2% | -28.9% | |
| Q2 2016 | -3.1% | -2.6% | +6.5% | |
| Q1 2016 | +1.9% | — | — | |
| Q4 2015 | -2.2% | — | — | |
| Q3 2015 | -6.2% | — | — | |
| Q2 2015 | -1.3% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | +3.5% | — | — | |
| Q3 2014 | -2.7% | — | — | |
| Q2 2014 | +7.8% | — | — | |
| Q2 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro